

RECONCILIATION OF SHARE CAPITAL AUDIT FOR THE QUARTER ENDED 31st MARCH 2026
(Regulation 76 of SEBI (Depository and Participant) Regulations, 2018)

1.	For the quarter ended	March 31, 2026					
2.	ISIN	INE03QK01018					
3.	Face Value	Re. 1.00/- each					
4.	Name of the Company	Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited)					
5.	Registered Office Address	# 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India Tel: 91 22 61539999					
6.	Correspondence Address	# 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India					
7.	Telephone & Fax No.	Ph: 040 – 23549414/3311					
8.	Email Address	investorservices@cohance.com					
9.	Names of the Stock exchanges where the Company's Securities are listed.	BSE Limited National Stock Exchange of India Ltd					
		Number of shares		% of Total Issued Capital			
10.	Issued Capital	38,25,67,140		100.00%			
11.	Listed Capital (exchange wise) (as per Company Records)	38,25,67,140–NSE		100.00%			
		38,25,67,140–BSE		100.00%			
12.	Held in dematerialized form in CDSL	1,46,20,445		3.82%			
13.	Held in dematerialized form in NSDL	36,75,95,132		96.09%			
14.	Physical	3,51,563		0.09%			
15.	Total No. of shares (12+13+14)	38,25,67,140		100.00%			
16.	Reasons for difference if any between (10&11, 10& 15, 11 & 15)	NIL					
17.	Certifying the details of changes in share capital during the quarter under consideration as per Table Below						
	Particulars*	No. of Shares	Applied or not applied for listing	Listed on Exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Approval pending for stock exchange (Specify names)
	NIL	NIL	NIL	NIL	NIL	NIL	NIL

*Rights, Bonus, Pref. Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital reduction, forfeiture, any other (Specify)

18.	Register of members electronically updated (Y/N)	Yes
19.	Reference of previous quarter with regards to excess dematerialized shares, if any	Nil
20.	Has the Company resolved the matter mentioned in point No. 19 above in the current quarter? If not, reason, why?	Not applicable
21.	Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with reasons for delay.	Nil
Total No. of demat requests		No. of requests
Confirmed after 21 days		Nil
Pending for more than 21 days		Nil
No. of shares		Nil
Reasons for delay		Nil
22.	Name, Telephone & Fax No. of Compliance Officer of the Company	*Sisir K. Mishra Ph: 040 – 23549414/3311
23.	Name, Address, Tel. & Fax No., Reg. No. of Auditor of the Company	CS. D. Renuka Practicing Company Secretary Plot No. 143, Flat No. 301, S V Kausalya Complex, Rajeev Nagar, Hyderabad - 500045 Mobile: +91-98480 59315 Reg. No: ACS11963
24.	Appointment of Common agency for share registry work, if yes (name and address)	KFin Technologies Limited Selenium Tower B, Plot 31-32 Gachibowli, Financial District Nanakramguda, Hyderabad – 500032
25.	Any other detail that the auditor may like to provide (e.g. BIFR Company, delisting from S.E, Company changed its name etc.)	NIL

Note: * Mr. Sisir K. Mishra has been appointed as the Company Secretary and Compliance Officer of the Company w.e.f. April 9, 2026, and Mr. Kundan Kumar Jha ceased to be Company Secretary, Compliance Officer and Head Legal w.e.f. February 04, 2026.

RENUKA
DURBHA

D. RENUKA

Company Secretary in Practice

C. P. No. 3460

ICSI Peer Review UIN: L2000TL172900

UDIN: A011963H000135746

Place: Hyderabad

Date: 18/04/2026